“One of the unique characteristics of metabolomics is its ability to reveal functionality. This is of great benefit as it can help to fill the gaps of other ’omics where insights may be lacking. Scientists can use metabolomics to provide a bridge with other ’omic approaches to more completely understand disease manifestation and state of the phenotype in the present time.” - Annie Evans, Director of R&D at Metabolon.

Why do some patients die from the COVID-19 coronavirus, while others have symptoms so mild they may not even realize they’re sick? How can treatments for the disease work in some cases, while having no positive effect in others?

GEN Bioprocessing April 2020 – Metabolomics can elevate bioprocessing through analysis of metabolite data streams. These same streams are critical to the Bioprocess 4.0 approach.

In this episode BioTechniques Digital Editor, Tristan Free speaks to Annie Evans, Director of R&D and David Foster, Vice President of Data and Informatics at Metabolon (NC, USA) about the latest developments in microbiome studies, including big data analysis, LCMS, alpha diversity and at-home fecal sample collection.

BioTechniques Digital Editors Abigail Sawyer and Tristan Free talk to Greg Michelotti of Metabolon (NC, USA) about metabolomics, its potential applications in precision medicine and the new $4 million research collaboration with the Canadian Longitudinal Study of Aging (CLSA) and other Canadian research groups to identify biomarkers for frailty.

Metabolon, a Morrisville-based precision health company specializing in a technology called metabolomics, is teaming with three Canadian research groups to discover humans’ frailty biomarkers, determine the severity of frailty and what can be done to help avoid the condition.

Some people age with relative ease, while others become medically frail. They lose strength, fatigue more easily, or their health, social and psychological challenges accumulate, and they must depend on others for assistance with activities of daily living.

Three national research groups and a leading biotechnology company are teaming together to discover the frailty biomarkers that may shed light on why some people become frail, determine the severity of frailty and what can be done to help avoid the condition.

To date there has been little consensus on the biological mechanisms underpinning frailty. Analysis of the CLSA samples will allow researchers to identify metabolites that will help to improve not only early prediction of frailty, but also lead to further research on treatments addressing specific aspects of frailty.

“One of the unique characteristics of metabolomics is its ability to reveal functionality. This is of great benefit as it can help to fill the gaps of other ’omics where insights may be lacking. Scientists can use metabolomics to provide a bridge with other ’omic approaches to more completely understand disease manifestation and state of the phenotype in the present time.” - Annie Evans, Director of R&D at Metabolon.

Why do some patients die from the COVID-19 coronavirus, while others have symptoms so mild they may not even realize they’re sick? How can treatments for the disease work in some cases, while having no positive effect in others?

GEN Bioprocessing April 2020 – Metabolomics can elevate bioprocessing through analysis of metabolite data streams. These same streams are critical to the Bioprocess 4.0 approach.

In this episode BioTechniques Digital Editor, Tristan Free speaks to Annie Evans, Director of R&D and David Foster, Vice President of Data and Informatics at Metabolon (NC, USA) about the latest developments in microbiome studies, including big data analysis, LCMS, alpha diversity and at-home fecal sample collection.

BioTechniques Digital Editors Abigail Sawyer and Tristan Free talk to Greg Michelotti of Metabolon (NC, USA) about metabolomics, its potential applications in precision medicine and the new $4 million research collaboration with the Canadian Longitudinal Study of Aging (CLSA) and other Canadian research groups to identify biomarkers for frailty.

Metabolon, a Morrisville-based precision health company specializing in a technology called metabolomics, is teaming with three Canadian research groups to discover humans’ frailty biomarkers, determine the severity of frailty and what can be done to help avoid the condition.

Some people age with relative ease, while others become medically frail. They lose strength, fatigue more easily, or their health, social and psychological challenges accumulate, and they must depend on others for assistance with activities of daily living.

Three national research groups and a leading biotechnology company are teaming together to discover the frailty biomarkers that may shed light on why some people become frail, determine the severity of frailty and what can be done to help avoid the condition.

To date there has been little consensus on the biological mechanisms underpinning frailty. Analysis of the CLSA samples will allow researchers to identify metabolites that will help to improve not only early prediction of frailty, but also lead to further research on treatments addressing specific aspects of frailty.